Stability over time of immature platelet fraction and comparison between EDTA and citrated whole blood samples.
EDTA
citrate
delayed analysis
immature platelet count
immature platelet fraction
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
22
06
2023
received:
12
04
2023
accepted:
10
07
2023
medline:
11
9
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Immature platelets (IP) are the youngest circulating platelets, released from megakaryocytes, and demonstrating increased dimensions, significant RNA content, and enhanced activity. Immature platelet research focuses on a differential diagnostic help in patients with thrombocytopenia. The objectives of this study were to compare the variability of IP in citrate and EDTA samples, and to determine stability over time. Fifty-six patients were included for comparison between EDTA and citrate whole blood sample collection. Among the patients, 28 had thrombocytopenia (platelet count < 150G/L). Platelet measurement impedancemetry and fluorimetry were performed with Sysmex XN-9000. The immature platelet fraction (IPF) and absolute immature platelet count (A-IPC) were determined with a fluorescent method. The mean value of platelet count with fluorescence was, in EDTA sample, 215 ± 171 and, in citrate sample, 153 ± 118 G/L. No significant difference was observed between IPF between EDTA and citrate (7.74 ± 6.68% vs. 8.45 ± 7.37%, p = 0.69), respectively. With the Bland-Altman analysis, the mean difference in the EDTA sample, between 1 and 24 h, was 8.06 ± 6.96% and 8.73 ± 7.12% for IPF, whereas in the citrate sample, between 1 and 6 h, it was 8.60 ± 7.29% and 7.54 ± 6.97%, for IPF. Comparing 1 h EDTA sample with 6 h citrate sample, the variance ratio was 0.974 (95% CI: 0.864-1.084) in IPF. We confirmed the potential to conduct IP measurements up to 24 h in the EDTA sample and IPF measurements in the citrate sample for up to 6 h. These results may be useful for the use of IPF, which is a promising parameter whose interest in clinical practice and standardization is not yet well defined.
Sections du résumé
BACKGROUND
BACKGROUND
Immature platelets (IP) are the youngest circulating platelets, released from megakaryocytes, and demonstrating increased dimensions, significant RNA content, and enhanced activity. Immature platelet research focuses on a differential diagnostic help in patients with thrombocytopenia. The objectives of this study were to compare the variability of IP in citrate and EDTA samples, and to determine stability over time.
METHODS
METHODS
Fifty-six patients were included for comparison between EDTA and citrate whole blood sample collection. Among the patients, 28 had thrombocytopenia (platelet count < 150G/L). Platelet measurement impedancemetry and fluorimetry were performed with Sysmex XN-9000. The immature platelet fraction (IPF) and absolute immature platelet count (A-IPC) were determined with a fluorescent method.
RESULTS
RESULTS
The mean value of platelet count with fluorescence was, in EDTA sample, 215 ± 171 and, in citrate sample, 153 ± 118 G/L. No significant difference was observed between IPF between EDTA and citrate (7.74 ± 6.68% vs. 8.45 ± 7.37%, p = 0.69), respectively. With the Bland-Altman analysis, the mean difference in the EDTA sample, between 1 and 24 h, was 8.06 ± 6.96% and 8.73 ± 7.12% for IPF, whereas in the citrate sample, between 1 and 6 h, it was 8.60 ± 7.29% and 7.54 ± 6.97%, for IPF. Comparing 1 h EDTA sample with 6 h citrate sample, the variance ratio was 0.974 (95% CI: 0.864-1.084) in IPF.
CONCLUSIONS
CONCLUSIONS
We confirmed the potential to conduct IP measurements up to 24 h in the EDTA sample and IPF measurements in the citrate sample for up to 6 h. These results may be useful for the use of IPF, which is a promising parameter whose interest in clinical practice and standardization is not yet well defined.
Identifiants
pubmed: 37475131
doi: 10.1002/jcla.24946
pmc: PMC10492457
doi:
Substances chimiques
Edetic Acid
9G34HU7RV0
Citric Acid
2968PHW8QP
Citrates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24946Informations de copyright
© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Eur J Haematol. 1999 Oct;63(4):239-44
pubmed: 10530412
J Clin Med. 2022 Mar 03;11(5):
pubmed: 35268474
Pediatr Blood Cancer. 2013 Jul;60(7):1198-203
pubmed: 23417964
Clin Chem Lab Med. 2014 Aug;52(8):1107-17
pubmed: 24807169
Oncology (Williston Park). 2015 Apr;29(4):282-94
pubmed: 25952492
Clin Lab Med. 2015 Mar;35(1):123-31
pubmed: 25676376
J Thromb Haemost. 2017 Jul;15(7):1511-1521
pubmed: 28457011
J Clin Lab Anal. 2014 Sep;28(5):341-8
pubmed: 24648166
Am J Clin Pathol. 2001 Mar;115(3):460-4
pubmed: 11246942
Semin Thromb Hemost. 2020 Apr;46(3):320-327
pubmed: 31858518
J Clin Lab Anal. 2023 Jul;37(13-14):e24946
pubmed: 37475131
Br J Haematol. 1998 Feb;100(2):351-7
pubmed: 9488626
Int J Lab Hematol. 2007 Feb;29(1):4-20
pubmed: 17224004
Biochem Med (Zagreb). 2018 Feb 15;28(1):010708
pubmed: 29472803
Int J Lab Hematol. 2021 Oct;43(5):966-972
pubmed: 33715283
Int J Lab Hematol. 2020 Oct;42(5):552-564
pubmed: 32304271
Int J Lab Hematol. 2021 Feb;43(1):e35-e37
pubmed: 33047880
Br J Haematol. 2004 Jul;126(1):93-9
pubmed: 15198738
Clin Chem Lab Med. 2013 Nov;51(11):2125-31
pubmed: 23800658
Thromb Haemost. 1995 Mar;73(3):506-13
pubmed: 7545322
Scand J Clin Lab Invest. 2017 Dec;77(8):658-664
pubmed: 29117724
J Clin Med. 2020 Mar 16;9(3):
pubmed: 32188124
Front Med (Lausanne). 2020 Dec 18;7:597734
pubmed: 33392220
J Clin Med. 2021 Feb 04;10(4):
pubmed: 33557431
Int J Lab Hematol. 2023 Feb;45(1):20-28
pubmed: 36093831
Clin Chem Lab Med. 2012 Mar 03;50(8):1387-91
pubmed: 22868803